Ajanta Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
October 31, 2023 at 04:12 am EDT
Share
Ajanta Pharma Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 10,284.4 million compared to INR 9,381 million a year ago. Revenue was INR 10,497.7 million compared to INR 9,784.5 million a year ago. Net income was INR 1,953 million compared to INR 1,566 million a year ago. Basic earnings per share from continuing operations was INR 15.51 compared to INR 12.22 a year ago. Diluted earnings per share from continuing operations was INR 15.5 compared to INR 12.22 a year ago.
For the six months, sales was INR 20,494.8 million compared to INR 18,890.3 million a year ago. Revenue was INR 20,925.7 million compared to INR 19,621.4 million a year ago. Net income was INR 4,034.2 million compared to INR 3,312.2 million a year ago. Basic earnings per share from continuing operations was INR 32.04 compared to INR 25.85 a year ago. Diluted earnings per share from continuing operations was INR 32.02 compared to INR 25.85 a year ago.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.